GlassScriptPhysician profile
Michael Paul Vrabec
NPI 1407883838
$19,790.76
in general payments reported to CMS, 2019-2025
37 companies · $2,661 in 2025
The $2,661 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,331 · 2020: $370 · 2021: $795 · 2022: $1,086 · 2023: $5,592 · 2024: $5,955 · 2025: $2,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,522 · Consulting Fee: $3,425 · Long Term Medical Supply Or Device Loan: $3,198 · Travel and Lodging: $2,039 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,521.59 |
| Consulting Fee | $3,425.00 |
| Long Term Medical Supply Or Device Loan | $3,197.66 |
| Travel and Lodging | $2,038.72 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,526.60 | 2019-2025 | Lensx, Clareon, Argos |
| Glaukos Corporation | $5,421.28 | 2019-2025 | Ce-Marked Kxla System, Idosetr, Idose |
| Carl Zeiss Meditec USA, INC. | $3,378.31 | 2023-2024 | Lumera 700, Artevo 800, Cirrus Hd-Oct |
| Rxsight INC | $1,218.70 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Dompe US, INC. | $860.55 | 2019-2025 | Oxervate |
| Abbvie INC. | $385.22 | 2022-2025 | Durysta |
| Bausch & Lomb Americas INC. | $356.42 | 2022-2025 | Ic-8 Apthera Iol, Miebo, Xiidra |
| Ocular Therapeutix, INC. | $241.17 | 2023-2024 | Dextenza |
| Allergan, INC. | $235.99 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $213.72 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| Ophtec USA, INC. | $196.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $170.25 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $167.22 | 2022-2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $153.14 | 2019-2021 | |
| Ivantis, INC | $150.00 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $146.84 | 2024-2025 | Acthar |
| The Cameron-Ehlen Group, INC. | $124.45 | 2019-2020 | |
| Astellas Pharma US INC | $108.47 | 2024-2025 | Izervay |
| Omeros Corporation | $93.19 | 2019-2021 | |
| Oyster Point Pharma, INC. | $84.37 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $82.20 | 2019-2021 | |
| Amgen INC. | $73.01 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $71.75 | 2024-2025 | Iheezo |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Coopervision INC. | $39.27 | 2021 | |
| Apellis Pharmaceuticals, INC. | $34.65 | 2023-2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $33.69 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $29.47 | 2022 | |
| Biogen, INC. | $19.81 | 2024 | Byooviz |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $17.23 | 2019 | |
| New World Medical,INC. | $17.17 | 2023 | |
| Aerie Pharmaceuticals, INC. | $17.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.73 | 2023 | Eylea |
| Lkc Technologies, INC. | $12.55 | 2023 | |
| Biotissue Holdings INC. | $10.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vrabec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.